Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388726 · ClinicalTrials.gov registry record · Phase 3
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 762
- Enrollment target
NCT00388726 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 762 participants.
The verdict
NCT00388726, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 762 participants
- Enrollment target
Study Summary
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.
Interventions
- DRUG Physician's Choice
- DRUG E7389
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 762 participants |
| Start Date | 2006-11 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00388726
The ClinicalTrials.gov registry entry for NCT00388726 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 762 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Physician's Choice is the first listed.
NCT00388726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00388726 about?
NCT00388726 is a clinical study titled "E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer". The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast canc...
What is the current status of trial NCT00388726?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 762 participants. The study started on 2006-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00388726?
The interventions under investigation include: Physician's Choice (DRUG), E7389 (DRUG).
Who is sponsoring clinical trial NCT00388726?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.